February 2013 FDA Recall Drug by Teva Pharmaceuticals Usa, Inc.
D-237-2013 - Failed Content Uniformity Specifications
This Class II drug recall was voluntarily initiated by Teva Pharmaceuticals Usa, Inc. on February 7, 2013 for the product Drug. The FDA reported the reason for recall as failed content uniformity specifications. The product was distributed in NC and the recall is currently terminated.
Recall Number: D-237-2013
Failed Content Uniformity Specifications: Recall is being carried out due to an out-of-specification result for content uniformity.
02-07-2013
04-10-2013
3 boxes
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Teva Pharmaceuticals USA, Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
NC
01-15-2014
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
CLONAZEPAM ORALLY DISINTERGRATING Tablets, USP, 0.5 mg, 60 tablets (10 blister cards of 6 tablets each), TEVA PHARMACEUTICALS USA, Sellersville PA 18960, NDC #0555-0096-96
Batch or Lot Expiration Information
Lot# 32900136A, Exp. 05/14